Sugi Predict

Sugi Predict / Compounds / SCHEMBL106845

SCHEMBL106845

SCHEMBL106845

CC(C)CCCC(=O)CC(C)C

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ CYP2C19 P33261 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ KDM1A O60341 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ PTPN1 P18031 2/20 0.37
▸ KDM4C Q9H3R0 2/20 0.36
▸ KDM4A O75164 1/20 0.36
▸ PHF8 Q9UPP1 1/20 0.36
▸ KDM2A Q9Y2K7 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16431601 0.91 KDM4C (0.46) CA1ALDH1A1TDP1CYP2C19BLM
SCHEMBL13879345 0.87 ALDH1A1 (0.48) CA1ALDH1A1TDP1CYP2C19CA2
SCHEMBL5613242 0.87 CA1 (0.48) CA1ALDH1A1TDP1BLMKDM1A
SCHEMBL4877127 0.86 CYP2C19 (0.42) CA1ALDH1A1TDP1CYP2C19CA2
SCHEMBL18087557 0.86 CA1 (0.39) CA1ALDH1A1TDP1CYP2C19BLM
SCHEMBL110158 0.84 CA1 (0.52) CA1ALDH1A1TDP1CYP2C19BLM
SCHEMBL11405869 0.82 BLM (0.39) CA1ALDH1A1TDP1BLMKDM1A
SCHEMBL2527461 0.82 CA1 (0.44) CA1BLMKDM1APTPN1KDM4C
SCHEMBL110410 0.82 CA1 (0.50) CA1BLMKDM1APTPN1KDM4C
SCHEMBL9575794 0.81 NFKB1 (0.39) ALDH1A1TDP1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 — — EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 — — EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 — — US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 — — US claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 — — WO claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 — — WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 — — EP disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 — — US disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 — — US disclosed
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-01-25 — — US disclosed
US-11872291-B2 Fibroblast activation protein (FAP)-targeted imaging and therapy PURDUE RESEARCH FOUNDATION (US) 2024-01-16 — — US disclosed
US-11834463-B2 High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders Technische Universität Darmstadt (DE) 2023-12-05 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
WO-2009097346-A2 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-06 — — WO disclosed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 — — US disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 — — US disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 — — WO disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 — — WO disclosed
US-20080288176-A1 Development of Prodrugs Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Noiety Using in Vitro/in Silico Predictions TAM YUN KAU 2008-11-20 — — US disclosed
CN-1229693-C Optical enhancement right photoetching rubber composite and sulfonium salt SUMITOMO CHEMICAL CO (JP) 2005-11-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV CA1 3229/4885ALDH1A1 1727/4885TDP1 4385/4885
US-11872291-B2 Fibroblast activation protein (FAP)-targeted imaging and therapy FAP, FIBP, FRS2 CA1 2914/4885ALDH1A1 1776/4885TDP1 2309/4885
US-11834463-B2 High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders FKBP1B, FKBP5, FKBP1A CA1 4776/4885ALDH1A1 4075/4885TDP1 3893/4885
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA CA1 2232/4885ALDH1A1 753/4885TDP1 2746/4885
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS SOS1, SOS2, SOST CA1 4555/4885ALDH1A1 3542/4885TDP1 1497/4885
US-20080288176-A1 Development of Prodrugs Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Noiety Using in Vitro/in Silico Predictions NOS1, NOS2, NOS3 CA1 990/4885ALDH1A1 171/4885TDP1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.